Comparative Pharmacology
Head-to-head clinical analysis: NORISODRINE versus VAPO ISO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORISODRINE versus VAPO ISO.
NORISODRINE vs VAPO-ISO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at beta-1 and beta-2 adrenergic receptors, causing positive inotropic and chronotropic effects on the heart and bronchodilation.
VAPO-ISO (isoproterenol) is a non-selective beta-adrenergic agonist that stimulates both beta-1 and beta-2 adrenergic receptors. It increases heart rate, contractility, and conduction velocity (beta-1), and causes bronchodilation and peripheral vasodilation (beta-2).
Intravenous: 0.5-5 mcg/min continuous infusion; initial rate 0.5 mcg/min, titrate to effect. Subcutaneous or intramuscular: 0.2 mg (0.2 mL of 1:1000 solution).
Inhalation: 1-2 inhalations of a 0.5% solution for acute bronchospasm; 0.5 mL of 1:200 solution via nebulizer every 4-6 hours as needed.
None Documented
None Documented
Terminal half-life is 2-3 minutes; too short for sustained action, requiring continuous IV infusion.
Terminal elimination half-life is 2–4 hours (mean 3 hours). In severe renal impairment (CrCl <30 mL/min), half-life may be prolonged to 8–12 hours, requiring dose adjustment.
Primarily renal excretion of unchanged drug (80-90%) and sulfate conjugates; minor biliary excretion (<5%).
Renal excretion of unchanged drug (30–50%) and hepatic metabolism to inactive metabolites. Fecal excretion is negligible (<2%).
Category C
Category C
Beta-Adrenergic Agonist
Beta-Adrenergic Agonist